Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

C-Path awards $1.7 million to advance five drug development projects

Critical Path Institute (C-Path) today announced that its Translational Therapeutics Accelerator has awarded $1,699,500 through five Bridging Research and Innovation in Drug Development Grants (BRIDGe).

22 Sep 2026

MLC1 auto-antibodies identified as possible trigger for NMOSD-like diseases

NMOSD is an inflammatory autoimmune disorder that damages support and supply cells in the central nervous system, known as astrocytes.

22 Sep 2026

German researchers aim to completely degrade breast cancer protein

Simply switching off a protein that helps breast cancer cells to grow? That is not enough for researchers at the University of Duisburg-Essen.

21 Sep 2026

HIV awareness emphasizes prevention, treatment and healthy aging

About 1.2 million people in the United States are living with HIV, or human immunodeficiency virus. Because of major advances in medical treatment and technology, people with HIV are living long, healthy lives.

18 Sep 2026

SARS-CoV-2 protein ORF8 drives macrophage infection and lung inflammation

In the sickest COVID-19 patients, the SARS-CoV-2 virus doesn't just cause severe damage by directly infecting airway cells.

18 Sep 2026

Antibody therapy teaches the immune system to control HIV

There is no cure for HIV. While scientists have made considerable progress in controlling the infection, patients still must take daily antiretroviral medication for the rest of their lives.

18 Sep 2026

Innate immune system variations determine vaccine side effects

Redness and pain at the injection site, fever, fatigue or headaches: vaccines can cause side effects, but their frequency and severity vary considerably from person to person.

17 Sep 2026

Targeted antibody therapy provides long-lasting relief from neuropathic pain

Pain is a natural protective mechanism that alerts the body to actual or potential injury. But when nerves themselves are damaged, they can generate abnormal pain signals even in the absence of a new injury.

16 Sep 2026

Study confirms continued effectiveness of antibodies and vaccines used to prevent RSV infections

An analysis of more than 60,000 respiratory syncytial virus (RSV) sequences from around the world found that viral variants associated with resistance to current RSV prevention tools remain rare, according to a study published Sept. 16 in Nature.

16 Sep 2026

Harvard scientists design evolutionary traps to stop viral mutations

When a virus mutates, the world usually finds out the hard way. Variants of influenza and SARS‑CoV‑2 can slip past vaccines and antibody drugs before scientists fully understand what has changed.

15 Sep 2026

Natural anti-NMDAR1 antibody may protect the brain following traumatic brain injury

Every year, an estimated 20 million people worldwide sustain a concussion or other traumatic brain injury (TBI), which leads to a two- to four-fold increase in the risk of depression, anxiety and post-traumatic stress disorder (PTSD).

15 Sep 2026

Stage 1 findings support continued pivotal phase evaluation of gotistobart

Patients with metastatic squamous non-small cell lung cancer (NSCLC) whose disease progressed following PD-(L)1 inhibitor therapy experienced a median overall survival of 18.5 months with the investigational anti-CTLA-4 antibody gotistobart compared with 10.0 months for patients receiving docetaxel, according to updated findings from Stage 1 of the Phase 3 PRESERVE-003 trial.

15 Sep 2026

Tam-Peli significantly extends survival in relapsed small-cell lung cancer

The phase III TAISHAN-302 trial found that tambotatug pelitecan (Tam-Peli, YL201), a novel anti-B7-H3 antibody-drug conjugate, significantly improved overall survival, progression-free survival and objective response rate compared with topotecan in patients with relapsed small-cell lung cancer (SCLC).

14 Sep 2026

Ivonescimab shows significant survival benefit for patients with PD-L1-positive NSCLC

Ivonescimab significantly prolonged overall survival compared with pembrolizumab as first-line treatment for patients with PD-L1-positive advanced non-small cell lung cancer (NSCLC), according to a prespecified interim analysis of the phase 3 HARMONi-2 trial presented today at the IASLC 2026 World Conference on Lung Cancer.

14 Sep 2026

Ris-Rez improves survival in patients with relapsed small-cell lung cancer

Results from the randomized Phase III ARTEMIS-008 trial show that risvutatug rezetecan (Ris-Rez), a B7-H3-directed antibody-drug conjugate, significantly improved overall survival compared with topotecan in patients with relapsed small-cell lung cancer (SCLC) whose disease progressed on or after platinum-based chemotherapy.

14 Sep 2026

Low discontinuation rates confirm manageable safety of iza-bren

An investigational EGFR x HER3 antibody-drug conjugate demonstrated promising efficacy with a tolerable safety profile in patients with previously treated EGFR-mutated non-small cell lung cancer (NSCLC), supporting selection of the 2.5 mg/kg dose for evaluation in the global Phase 3 IZABRIGHT-Lung01 registrational study.

12 Sep 2026

Tumor DNA clearance reaches 39% in novel immunomodulator and ADC combination

The investigational combination of pumitamig and elfetabart drozuntecan (elfe-D) demonstrated a manageable safety profile and encouraging early antitumor activity in patients with small cell lung cancer (SCLC), according to first clinical data from the ongoing Phase 1b/2 BNT324-01 trial presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC).

12 Sep 2026